COMP <GO>
BBIO vs SMMT // NET PROFIT MARGIN
BridgeBio Pharma Inc. (NASDAQ) VS. Summit Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BBIO 5
— SMMT 5
▲ NET PROFIT MARGIN LEADER: SMMT
LAST: $75.00 (+0.06%) • MKT CAP: $14.60B
net-margins
-60.00%
LAST: $14.80 (-7.67%) • MKT CAP: $12.82B
net-margins
-29.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BBIO VS. SMMT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BBIO | SMMT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 95.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.23% | -2.50% | -0.73 | SMMT | /fcf-yield <GO> |
| Operating Margin | -60.00% | -36.30% | -23.70 | SMMT | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -60.00% | -29.80% | -30.20 | SMMT | /net-margins <GO> |
| Revenue Growth (YoY) | 126.30% | 11.00% | +115.30 | BBIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 26.00 | -25.55 | SMMT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 5/9 | -1.00 | SMMT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.9 | 50.5 | +13.40 | BBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.97 | +0.03 | BBIO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 34.0x | -1.00 | BBIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.60B | $12.82B | $1.78B | BBIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BBIO REV | SMMT REV | BBIO GROSS % | SMMT GROSS % | BBIO FCF | SMMT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $502.1M | $3.57B | 95.8% | — | -$447.0M | -$323.6M |
| FY 2024 | $221.9M | $632.8M | 98.3% | — | -$521.7M | -$142.2M |
| FY 2023 | $9.3M | $1.71B | — | — | -$528.1M | -$76.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BBIO // BETA 1.00
SMMT // BETA 0.97